These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16157424)

  • 1. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components.
    Hahn UK; Boehm R; Beyer W
    Vaccine; 2006 May; 24(21):4569-71. PubMed ID: 16157424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination.
    Hahn UK; Alex M; Czerny CP; Böhm R; Beyer W
    Int J Med Microbiol; 2004 Jul; 294(1):35-44. PubMed ID: 15293452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BclA and toxin antigens augment each other to protect NMRI mice from lethal Bacillus anthracis challenge.
    Köhler SM; Baillie LW; Beyer W
    Vaccine; 2015 Jun; 33(24):2771-7. PubMed ID: 25917676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid.
    Cui Z; Sloat BR
    Int J Pharm; 2006 Jul; 317(2):187-91. PubMed ID: 16730934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.
    Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL
    Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
    Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
    Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
    Price BM; Liner AL; Park S; Leppla SH; Mateczun A; Galloway DR
    Infect Immun; 2001 Jul; 69(7):4509-15. PubMed ID: 11401993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.
    Herrmann JE; Wang S; Zhang C; Panchal RG; Bavari S; Lyons CR; Lovchik JA; Golding B; Shiloach J; Lu S
    Vaccine; 2006 Jul; 24(31-32):5872-80. PubMed ID: 16790303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of an anthrax DNA vaccine with electroporation.
    Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
    Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
    Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
    Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
    Sloat BR; Cui Z
    J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic immunization against anthrax.
    Galloway D; Liner A; Legutki J; Mateczun A; Barnewall R; Estep J
    Vaccine; 2004 Apr; 22(13-14):1604-8. PubMed ID: 15068841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.
    Livingston BD; Little SF; Luxembourg A; Ellefsen B; Hannaman D
    Vaccine; 2010 Jan; 28(4):1056-61. PubMed ID: 19896452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction, crystal structure and application of a recombinant protein that lacks the collagen-like region of BclA from Bacillus anthracis spores.
    Liu CQ; Nuttall SD; Tran H; Wilkins M; Streltsov VA; Alderton MR
    Biotechnol Bioeng; 2008 Mar; 99(4):774-82. PubMed ID: 17879302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
    Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
    Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen.
    Brahmbhatt TN; Darnell SC; Carvalho HM; Sanz P; Kang TJ; Bull RL; Rasmussen SB; Cross AS; O'Brien AD
    Infect Immun; 2007 Nov; 75(11):5240-7. PubMed ID: 17785478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.
    Cybulski RJ; Sanz P; McDaniel D; Darnell S; Bull RL; O'Brien AD
    Vaccine; 2008 Sep; 26(38):4927-39. PubMed ID: 18657585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
    Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
    Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.